@article {7674,
	title = {Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer},
	journal = {International Journal of Cardiology},
	volume = {154},
	year = {2012},
	note = {Cited By :3Export Date: 21 February 2017},
	month = {2012},
	pages = {341 - 344},
	keywords = {Bevacizumab, Neovascularization, Systolic dysfunction, Vasa vasorum},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855942935\&doi=10.1016\%2fj.ijcard.2011.10.115\&partnerID=40\&md5=2acfac08c8b575bf4bc0d38fbb501a9c},
	author = {Stefanadis, C. and Synetos, A. and Tousoulis, D. and Tsiamis, E. and Michelongona, A. and Zagouri, F. and Bamias, A. and Dimopoulos, M.A. and Kyvelou, S. and Kapelakis, I. and Toutouzas, K.}
}
